Edition:
United Kingdom

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.79USD
12 Dec 2017
Change (% chg)

$0.20 (+3.58%)
Prev Close
$5.59
Open
$5.59
Day's High
$5.90
Day's Low
$5.59
Volume
89,481
Avg. Vol
98,026
52-wk High
$8.62
52-wk Low
$4.98

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics Announces Proposed Public Offering
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING.ARATANA THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.ARATANA THERAPEUTICS INC - ‍ALL OF SHARES ARE BEING OFFERED BY ARATANA THERAPEUTICS​.  Full Article

ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Elanco Animal Health::ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE.CO, ARATANA THERAPEUTICS ANNOUNCED EMA'S CVMP ADOPTED POSITIVE OPINION TO RECOMMEND MARKETING AUTHORIZATION OF GALLIPRANT IN EU.FOLLOWING THE POSITIVE OPINION, EC WILL COMPLETE REGULATORY PROCESS FOR FINAL DECISION ON MARKETING AUTHORISATION IN EARLY 2018.  Full Article

Aratana Therapeutics reports Q3 loss per share of $0.21
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $6.2 million.  Full Article

Aratana Therapeutics announces launch of Entyce
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution).Aratana Therapeutics - co is making Entyce commercially available to veterinarians in United States for appetite stimulation in dogs​.  Full Article

Aratana Therapeutics granted FDA approval of Nocita
Monday, 15 Aug 2016 

Aratana Therapeutics Inc : Aratana Therapeutics granted FDA approval of Nocita® (bupivacaine liposome injectable suspension) .Anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana posts Q2 EPS $0.61
Thursday, 4 Aug 2016 

Aratana Therapeutics Inc : Q2 earnings per share $0.61 . Aratana therapeutics reports second quarter 2016 financial results .Q2 revenue $38 million versus $45 million.  Full Article

Aratana Therapeutics posts Q2 earnings per share $0.61
Thursday, 4 Aug 2016 

Aratana Therapeutics Inc : Q2 revenue $38 million versus $230,000 . Aratana Therapeutics reports second quarter 2016 financial results .Q2 earnings per share $0.61.  Full Article

Aratana Therapeutics files for FDA approval of Nocita
Thursday, 30 Jun 2016 

Aratana Therapeutics Inc : Aratana Therapeutics files for FDA approval of Nocita(bupivacaine liposome injectable suspension) . Says animal drug user fee act (ADUFA) date for approval is August 28, 2016 . Aratana anticipates Nocita will be commercially available to veterinarians in fall of 2016 .Says anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana Therapeutics receives CMC technical section complete letter
Thursday, 2 Jun 2016 

Aratana Therapeutics Inc : Received a technical section complete letter for chemistry, manufacturing and controls for nocita . Aratana Therapeutics receives CMC technical section complete letter for post-operative pain therapeutic .If nocita receives FDA approval, aratana expects to commence commercialization in late-2016.  Full Article

Aratana Therapeutics says FDA approved its drug for appetite stimulation in dogs
Tuesday, 17 May 2016 

Aratana Therapeutics Inc : Intends to commercially launch Entyce in conjunction with North American Veterinary Conference in February 2017 .Aratana Therapeutics granted FDA approval of Entyce® (capromorelin oral solution).  Full Article